Integrated Filing — IndAS

General information about company
Scrip Code	500420
NSE Symbol	TORNTPHARM
MSEI Symbol	NOTLISTED
ISIN	INE685A01028
Name of company	TORRENT PHARMACEUTICALS LIMITED
Type of company	Main Board
Class of security	Equity
Date of start of financial year	01-Apr-2024
Date of end of financial year	31-Mar-2025
Date of board meeting when results were approved	20-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	13-May-2025
Description of presentation currency	INR (in Actuals)
Reporting Type	Quarterly
Reporting Quarter	Fourth quarter
Nature of report standalone or consolidated	Consolidated
Whether results are audited or unaudited for the quarter ended	Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Audited
Segment Reporting	Single segment
Description of single segment	Generic Formulation Business
Start date and time of board meeting	20-May-2025   14:20:00
End date and time of board meeting	20-May-2025   16:30:00
Whether cash flow statement is applicable on company	Yes
Type of cash flow statement	Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification	Declaration of unmodified opinion

Financial Results Ind-AS
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-Jan-2025	01-Apr-2024
B	Date of end of reporting period	31-Mar-2025	31-Mar-2025
C	Whether results are audited or unaudited	Audited	Audited
D	Nature of report standalone or consolidated	Consolidated	Consolidated
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1	Income
	Revenue from operations	29590000000	115160000000
	Other income	-180000000	230000000
	Total income	29410000000	115390000000
2	Expenses
(a)	Cost of materials consumed	4020000000	15200000000
(b)	Purchases of stock-in-trade	4160000000	15310000000
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-870000000	-2750000000
(d)	Employee benefit expense	5610000000	22030000000
(e)	Finance costs	560000000	2520000000
(f)	Depreciation, depletion and amortisation expense	2010000000	7950000000
(f)	Other Expenses
1	Other Expenses	7030000000	28160000000
	Total other expenses	7030000000	28160000000
	Total expenses	22520000000	88420000000
3	Total profit before exceptional items and tax	6890000000	26970000000
4	Exceptional items	-240000000	-240000000
5	Total profit before tax	6650000000	26730000000
6	Tax expense
7	Current tax	1840000000	6190000000
8	Deferred tax	-170000000	1430000000
9	Total tax expenses	1670000000	7620000000
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
11	Net Profit Loss for the period from continuing operations	4980000000	19110000000
12	Profit (loss) from discontinued operations before tax	0	0
13	Tax expense of discontinued operations	0	0
14	Net profit (loss) from discontinued operation after tax	0	0
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
16	Total profit (loss) for period	4980000000	19110000000
17	Other comprehensive income net of taxes	360000000	-930000000
18	Total Comprehensive Income for the period	5340000000	18180000000
19	Total profit or loss, attributable to
	Profit or loss, attributable to owners of parent	4980000000	19110000000
	Total profit or loss, attributable to non-controlling interests	0	0
20	Total Comprehensive income for the period attributable to
	Comprehensive income for the period attributable to owners of parent	5340000000	18180000000
	Total comprehensive income for the period attributable to owners of parent non-controlling interests	0	0
21	Details of equity share capital
	Paid-up equity share capital	1692300000	1692300000
	Face value of equity share capital	5	5
27	Details of debt securities
22	Reserves excluding revaluation reserve		74220000000
23	Earnings per share
i	Earnings per equity share for continuing operations
	Basic earnings (loss) per share from continuing operations	14.71	56.47
	Diluted earnings (loss) per share from continuing operations	14.71	56.47
ii	Earnings per equity share for discontinued operations
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
ii	Earnings per equity share
	Basic earnings (loss) per share from continuing and discontinued operations	14.71	56.47
	Diluted earnings (loss) per share from continuing and discontinued operations	14.71	56.47
24	Debt equity ratio	0.004	0.004
25	Debt service coverage ratio	0.0491	0.0387
26	Interest service coverage ratio	0.1366	0.1243
27	Disclosure of notes on financial results		1. Exceptional item for the quarter and year ended March 31, 2025, relates to a demand raised by the National Pharmaceutical Pricing Authority (NPPA) in 2017 concerning alleged overcharging, which was under judicial consideration before the Hon’ble Gujarat High Court. During the year, the parent company submitted detailed representations, which were favourably considered by the NPPA. As a result, the parent company’s legal exposure was substantially reduced. Following the issuance of a revised demand by the NPPA, the parent company opted to settle the litigation and bring the matter to a definitive close. n n2. The Income Tax Act, 1961, provides an option to the parent company for paying tax at reduced rates (lower tax rate) as per the provisions/conditions defined in the Income Tax Act, 1961 (Section 115BAA).With reference to the same, the parent company had previously assessed the option of availing the lower tax rate under Section 115BAA, in future years, and accordingly applied a mixed tax rate of 25.17% for deferred tax items expected to reverse after transitioning into new regime and 34.94% for those expected to reverse before the transition. Based on the current-year evaluation of available MAT credits and deductions under Chapter VIA as at March 31, 2025, the parent company has now assessed that it will transition to the new tax regime from FY 2025-26. Consequently, deferred tax balances expected to reverse in or after FY 2025-26 have been remeasured at 25.17%, resulting in a net reversal of deferred tax liabilities of Rs. 151 crores for the year ended March 31, 2025.

Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio

Statement of Asset and Liabilities
Particulars		Year ended (dd-mm-yyyy)
Date of start of reporting period		01-Apr-2024
Date of end of reporting period		31-Mar-2025
Whether results are audited or unaudited		Audited
Nature of report standalone or consolidated		Consolidated
	Assets
1	Non-current assets
	Property, plant and equipment	34550000000
	Capital work-in-progress	3670000000
	Investment property	0
	Goodwill	3390000000
	Other intangible assets	41520000000
	Intangible assets under development	1110000000
	Biological assets other than bearer plants	0
	Investments accounted for using equity method	0
	Non-current financial assets
	Non-current investments	440000000
	Trade receivables, non-current	0
	Loans, non-current	30000000
	Other non-current financial assets	330000000
	Total non-current financial assets	800000000
	Deferred tax assets (net)	5950000000
	Other non-current assets	2680000000
	Total non-current assets	93670000000
2	Current assets
	Inventories	25410000000
	Current financial asset
	Current investments	1120000000
	Trade receivables, current	18670000000
	Cash and cash equivalents	5730000000
	Bank balance other than cash and cash equivalents	60000000
	Loans, current	50000000
	Other current financial assets	1830000000
	Total current financial assets	27460000000
	Current tax assets (net)	0
	Other current assets	3360000000
	Total current assets	56230000000
3	Non-current assets classified as held for sale	0
4	Regulatory deferral account debit balances and related deferred tax Assets	0
	Total assets	149900000000
	Equity and liabilities
1	Equity
	Equity attributable to owners of parent
	Equity share capital	1690000000
	Other equity	74220000000
	Total equity attributable to owners of parent	75910000000
	Non controlling interest	0
	Total equity	75910000000
2	Liabilities
	Non-current liabilities
	Non-current financial liabilities
	Borrowings, non-current	11920000000
	Trade payables, non-current
	(A) Total outstanding dues of micro enterprises and small enterprises	0
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	0
	Total Trade payable	0
	Other non-current financial liabilities	1600000000
	Total non-current financial liabilities	13520000000
	Provisions, non-current	5010000000
	Deferred tax liabilities (net)	8290000000
	Deferred government grants, Non-current	0
	Other non-current liabilities	0
	Total non-current liabilities	26820000000
	Current liabilities
	Current financial liabilities
	Borrowings, current	18340000000
	Trade payables, current
	(A) Total outstanding dues of micro enterprises and small enterprises	230000000
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	17970000000
	Total Trade payable	18200000000
	Other current financial liabilities	4230000000
	Total current financial liabilities	40770000000
	Other current liabilities	1360000000
	Provisions, current	4080000000
	Current tax liabilities (Net)	960000000
	Deferred government grants, Current	0
	Total current liabilities	47170000000
3	Liabilities directly associated with assets in disposal group classified as held for sale	0
4	Regulatory deferral account credit balances and related deferred tax liability	0
	Total liabilities	73990000000
	Total equity and liabilites	149900000000
	Disclosure of notes on assets and liabilities

Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars		3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-Jan-2025	01-Apr-2024
Date of end of reporting period		31-Mar-2025	31-Mar-2025
Whether accounts are audited or unaudited		Audited	Audited
Nature of report standalone or consolidated		Consolidated	Consolidated
1	Segment Revenue (Income)
	(net sale/income from each segment should be disclosed)
	Total Segment Revenue
	Less: Inter segment revenue
	Revenue from operations
2	Segment Result
	Profit (+) / Loss (-) before tax and interest from each segment
	Total Profit before tax
	i. Finance cost
	ii. Other Unallocable Expenditure net off Unallocable income
	Profit before tax
3	(Segment Asset - Segment Liabilities)
	Segment Asset
	Total Segment Asset
	Un-allocable Assets	null	null
	Net Segment Asset	null	null
4	Segment Liabilities
	Segment Liabilities
	Total Segment Liabilities
	Un-allocable Liabilities	null	null
	Net Segment Liabilities	null	null
	Disclosure of notes on segments

Other Comprehensive Income
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-Jan-2025	01-Apr-2024
B	Date of end of reporting period	31-Mar-2025	31-Mar-2025
C	Whether results are audited or unaudited	Audited	Audited
D	Nature of report standalone or consolidated	Consolidated	Consolidated
	Other comprehensive income [Abstract]
1	Amount of items that will not be reclassified to profit and loss
1	Amount of items that will not be reclassified to profit and loss	-90000000	-280000000
	Total Amount of items that will not be reclassified to profit and loss	-90000000	-280000000
2	Income tax relating to items that will not be reclassified to profit or loss	10000000	-60000000
3	Amount of items that will be reclassified to profit and loss
1	Amount of items that will be reclassified to profit and loss	520000000	-780000000
	Total Amount of items that will be reclassified to profit and loss	520000000	-780000000
4	Income tax relating to items that will be reclassified to profit or loss	60000000	-70000000
5	Total Other comprehensive income	360000000	-930000000

Cash flow statement, indirect
Particulars				Year ended (dd-mm-yyyy)
A	Date of start of reporting period			2024-04-01
B	Date of end of reporting period			2025-03-31
C	Whether results are audited or unaudited			Audited
D	Nature of report standalone or consolidated			Consolidated
Part I	Blue color marked fields are non-mandatory.
	Statement of cash flows
	Cash flows from used in operating activities
	Profit before tax			26730000000
	Adjustments for reconcile profit (loss)
	Adjustments for finance costs			2520000000
	Adjustments for decrease (increase) in inventories			-2620000000
	Adjustments for decrease (increase) in trade receivables, current			170000000
	Adjustments for decrease (increase) in trade receivables, non-current			0
	Adjustments for decrease (increase) in other current assets			-520000000
	Adjustments for decrease (increase) in other non-current assets			0
	Adjustments for other financial assets, non-current			0
	Adjustments for other financial assets, current			0
	Adjustments for other bank balances			0
	Adjustments for increase (decrease) in trade payables, current			-2780000000
	Adjustments for increase (decrease) in trade payables, non-current			0
	Adjustments for increase (decrease) in other current liabilities			940000000
	Adjustments for increase (decrease) in other non-current liabilities			0
	Adjustments for depreciation and amortisation expense			7950000000
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss			0
	Adjustments for provisions, current			0
	Adjustments for provisions, non-current			0
	Adjustments for other financial liabilities, current			0
	Adjustments for other financial liabilities, non-current			0
	Adjustments for unrealised foreign exchange losses gains			-150000000
	Adjustments for dividend income			0
	Adjustments for interest income			200000000
	Adjustments for share-based payments			0
	Adjustments for fair value losses (gains)			0
	Adjustments for undistributed profits of associates			0
	Other adjustments for which cash effects are investing or financing cash flow			-180000000
	Other adjustments to reconcile profit (loss)			20000000
	Other adjustments for non-cash items			0
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships			0
	Total adjustments for reconcile profit (loss)			5150000000
	Net cash flows from (used in) operations			31880000000
	Dividends received			0
	Interest paid			0
	Interest received			0
	Income taxes paid (refund)			6030000000
	Other inflows (outflows) of cash			0
	Net cash flows from (used in) operating activities			25850000000
	Cash flows from used in investing activities
	Cash flows from losing control of subsidiaries or other businesses			0
	Cash flows used in obtaining control of subsidiaries or other businesses			0
	Other cash receipts from sales of equity or debt instruments of other entities			450000000
	Other cash payments to acquire equity or debt instruments of other entities			0
	Other cash receipts from sales of interests in joint ventures			0
	Other cash payments to acquire interests in joint ventures			0
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships			0
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships			100000000
	Proceeds from sales of property, plant and equipment			180000000
	Purchase of property, plant and equipment			6110000000
	Proceeds from sales of investment property			0
	Purchase of investment property			0
	Proceeds from sales of intangible assets			0
	Purchase of intangible assets			0
	Proceeds from sales of intangible assets under development			0
	Purchase of intangible assets under development			0
	Proceeds from sales of goodwill			0
	Purchase of goodwill			0
	Proceeds from biological assets other than bearer plants			0
	Purchase of biological assets other than bearer plants			0
	Proceeds from government grants			0
	Proceeds from sales of other long-term assets			0
	Purchase of other long-term assets			0
	Cash advances and loans made to other parties			0
	Cash receipts from repayment of advances and loans made to other parties			0
	Cash payments for future contracts, forward contracts, option contracts and swap contracts			0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts			0
	Dividends received			0
	Interest received			200000000
	Income taxes paid (refund)			0
	Other inflows (outflows) of cash			-20000000
	Net cash flows from (used in) investing activities	-5400000000
	Cash flows from used in financing activities
	Proceeds from changes in ownership interests in subsidiaries			0
	Payments from changes in ownership interests in subsidiaries			0
	Proceeds from issuing shares			0
	Proceeds from issuing other equity instruments			0
	Payments to acquire or redeem entity's shares			0
	Payments of other equity instruments			0
	Proceeds from exercise of stock options			0
	Proceeds from issuing debentures notes bonds etc			0
	Proceeds from borrowings			0
	Repayments of borrowings			9260000000
	Payments of lease liabilities			270000000
	Dividends paid			10830000000
	Interest paid			2620000000
	Income taxes paid (refund)			0
	Other inflows (outflows) of cash			0
	Net cash flows from (used in) financing activities			-22980000000
	Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes			-2530000000
	Effect of exchange rate changes on cash and cash equivalents
	Effect of exchange rate changes on cash and cash equivalents			-90000000
	Net increase (decrease) in cash and cash equivalents			-2620000000
	Cash and cash equivalents cash flow statement at beginning of period			8350000000
	Cash and cash equivalents cash flow statement at end of period			5730000000